Pharmacoeconomics--an aid to better decision-making.
نویسندگان
چکیده
OBJECTIVES The first aim of this workshop was to define pharmacoeconomic concepts and terminology. Pharmacoeconomics can be defined as the branch of economics that uses cost-benefit, cost-effectiveness, cost-minimization, cost-of-illness and cost-utility analyses to compare pharmaceutical products and treatment strategies. Economic evaluations provide healthcare decision-makers with valuable information, allowing optimal allocation of limited resources. However, pharmacoeconomics is based on long-term benefits, whereas physicians are typically forced to seek immediate savings. The second aim was to review pharmacoeconomic studies in the field of onychomycosis and finally to discuss future perspectives. RESULTS AND CONCLUSIONS We discussed current pharmacoeconomic issues on the management of onychomycosis. Consensus was reached on the following issues: * Published pharmacoeconomic studies concerning onychomycosis are flawed. Future studies should be based on internationally validated principles and appropriate models. The fact that costs of different drugs, laboratory examinations and physician visits vary worldwide should be considered. Cost-benefit studies are required. * The National Institute for Clinical Excellence (NICE) recommendations are often considered in countries other than the UK, even when not adapted to the country in question. * Generic drugs might reduce costs, but this depends on their effectiveness (bioavailability). * Sampling requests affect the economic cost (dependent on methodology, which depends on country) and physicians often trust their instincts even when tests are repeatedly negative. * The cost of adverse event management is usually considered to be 10%; this may be too high for onychomycosis, as treatments are relatively safe without severe side-effects. * Probability of recurrence for each drug should be determined. * Need for disease severity standardization, definition of diagnostic criteria and successful treatment (mycological and clinical cure).
منابع مشابه
Better Reimbursement Decision-Making Based on Expected Cost-Effectiveness: Using Value of Information Decision Analysis to Improve The Design and Efficacy of A Phase Iii Program for Erlotinib.
متن کامل
Is there a role for pharmacoeconomics in developing countries?
The special issue of PharmacoEconomics pertaining to developing nations was a welcome move, with authors discussing various themes relating to pharmaceutical economics. The topics discussed included cost-effectiveness analyses and the future of health technology assessment (HTA) in healthcare decisionmaking in the greater Asia region. However, papers in this special issue did not provide an ans...
متن کاملMultiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
Health care decisions are complex and involve confronting trade-offs between multiple, often conflicting, objectives. Using structured, explicit approaches to decisions involving multiple criteria can improve the quality of decision making and a set of techniques, known under the collective heading multiple criteria decision analysis (MCDA), are useful for this purpose. MCDA methods are widely ...
متن کاملTools for health care decision making: observational studies, modeling studies, and network meta-analyses.
Comparative effectiveness research incorporates study designs extending beyond the randomized controlled trial (RCT) [1], which is the touchstone for demonstrating therapeutic efficacy. The litany of RCT flaws is often recited: not real world, not real patients, not real settings, not available, not timely, and not affordable. Although not every RCT is well designed, there are established narra...
متن کاملApplication of an integrated decision-making approach based on FDAHP and PROMETHEE for selection of optimal coal seam for mechanization; A case study of the Tazareh coal mine complex, Iran
Increasing the production rate and minimizing the related costs, while optimizing the safety measures, are nowadays’ most important tasks in the mining industry. To these ends, mechanization of mines could be applied, which can result in significant cost reductions and higher levels of profitability for underground mines. The potential of a coal mine mechanization depends on some important fact...
متن کاملMarket Access and Reimbursement: The Increasing Role of Real-World Evidence.
Randomized controlled trials (RCTs) have historically been considered the primary source of evidence to support decision-making in market access and reimbursement. However, thanks to significant progress in capturing data through computerized systems and making these data available, real-world evidence (RWE) has been increasingly considered by manufacturers and payers. Despite initiatives and r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the European Academy of Dermatology and Venereology : JEADV
دوره 19 Suppl 1 شماره
صفحات -
تاریخ انتشار 2005